1/7
07:11 am
lrmr
Larimar Therapeutics (NASDAQ:LRMR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Low
Report
Larimar Therapeutics (NASDAQ:LRMR) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
12/18
08:00 am
lrmr
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
11/5
07:00 am
lrmr
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Medium
Report
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
10/30
06:00 pm
lrmr
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
Medium
Report
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
10/29
12:10 pm
lrmr
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
10/28
10:00 am
lrmr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
10/23
10:00 am
lrmr
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
10/22
12:16 pm
lrmr
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
Low
Report
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR